Overview
The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.
Eligibility
Inclusion Criteria:
- cartilaginous reconstruction by autologous transplant or collagenous chondro-inducing knee matrix
- \> 18 years
Exclusion Criteria:
- Other cartilaginous reconstruction techniques,
- other than knee joint


